Raffi Tachdjian

Raffi Tachdjian

Auto-generated profile, based on publicly available information

Raffi Tachdjian

University of California Los Angeles David Geffen School of Medicine

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2023 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Open access
SKSorena Kiani-Alikhan
Sorena Kiani-Alikhan
RGRichard Gower
Richard Gower
Timothy CraigTimothy Craig
Timothy Craig
HWHarold James Wedner
Harold James Wedner
TKTamar Kinaciyan
Tamar Kinaciyan
WLWilliam R. Lumry
William R. Lumry
Berotralstat is a first-line, once-daily oral plasma kallikrein inhibitor approved for prophylaxis of hereditary angioedema (HAE) attacks in patients ≥12 years. This analysis examined the safety and effectiveness of long-term prophylaxis with berotralstat. APeX-2 was a Phase 3, parallel-group, multicenter trial in patients with HAE caused by C1 inhibitor deficiency (NCT03485911). Part 1 was a randomized, double-blind, placebo-controlled evaluation of 150 and 110 mg berotralstat over 24 weeks. In Part 2, berotralstat-treated patients continued the same treatment and placebo-treated patients were re-randomized to 150 or 110 mg berotralstat for 24 weeks. In Part 3, all patients were treated with open-label berotralstat at 150 mg, which could be continued for up to an additional 4 years. In Part 3, the primary endpoint was long-term safety and tolerability. Secondary endpoints included HAE attack rates and quality of life (QoL). Eighty-one patients entered Part 3. Treatment-emergent adverse events (TEAEs) occurred in 82.7% of patients, with most being mild or moderate in severity. The most common TEAEs were nasopharyngitis, urinary tract infection, abdominal pain, arthralgia, coronavirus infection, and diarrhea. Drug-related TEAEs occurred in 14.8% of patients, but none were serious. For patients who completed 96 weeks of berotralstat treatment (n=70), mean (standard error) change in attack rate from baseline was -2.21 (0.20) attacks/month. Clinically meaningful improvements in QoL were also observed, with the largest improvements in the functioning domain. Berotralstat was generally well tolerated, provided rapid and sustained reductions in HAE attacks, and improved QoL over 96 weeks.

26 July 2021 in Postgraduate Medicine
Verified
Journal Article
Closed access
RTRaffi Tachdjian
Raffi Tachdjian
DJDouglas T. Johnston
Douglas T. Johnston
A clinical vignette illustrates a typical presentation of a patient seeking help for acute angioedema. Despite the risks of SARS-CoV-2 (COVID-19) exposure, it is critical to evaluate patients with acute angioedema in person, because there is always the potential for angioedema to progress to the head, neck, or lungs, which can rapidly compromise the airways and require immediate intervention to avoid potential asphyxiation. There are three mediators of angioedema, histamine, leukotriene, or bradykinin, each requiring different management. This article provides clinicians essential information for differentiating between these types of angioedema, including an overview of the underlying pathogenies of angioedema, and the subjective and objective findings that are useful in differentiating between angioedema types. The article ends with the appropriate management for each type of acute angioedema, including the medications approved by the FDA for on-demand treatment of an HAE attack.

7 October 2014 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
RTRaffi Tachdjian
Raffi Tachdjian
JKJanet J. Keller
Janet J. Keller
MPMichael Pfeffer
Michael Pfeffer
Good’s syndrome is a relatively rare immunodeficiency condition that presents in the fourth or fifth decade of life and is defined by hypogammaglobulinemia in the setting of a thymoma. The humoral defect may be severe enough to cause an absence in B cells, with a consequent recurrence of sinopulmonary disease, chronic non-infectious diarrhea and opportunistic infections. The prognosis in patients with Good’s syndrome appears to be worse than in those with X-linked agammaglobulinemia (XLA) and common variable immune deficiency (CVID). There have only been three cases of Good’s syndrome associated with mycobacterium, and only one case with a cavitary lesion in the lungs. We present here a unique case of Good’s syndrome with a non-mycobacterial cavitary lesion.

29 August 2025 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Open access
HFHenriette Farkas
Henriette Farkas
JAJohn Anderson
John Anderson
LBLaurence Bouillet
Laurence Bouillet
TCTeresa Caballero
Teresa Caballero
MCMauro Cancian
Mauro Cancian
MMMarcus Maurer
Marcus Maurer
Poor compliance with hereditary angioedema guidelines for on-demand treatment is common due to challenges with parenteral administration. Sebetralstat, an oral plasma kallikrein inhibitor, demonstrated faster times to beginning of symptom relief, reduction in attack severity, and complete resolution than placebo in the phase 3 KONFIDENT trial (NCT05259917). This analysis evaluated long-term safety and effectiveness of sebetralstat in KONFIDENT-S (NCT05505916), an ongoing, 2-year, open-label extension study. Enrolled participants ≥12 years with hereditary angioedema with C1-inhibitor deficiency administered sebetralstat 600mg for each attack as early as possible, regardless of severity or location. incidence of treatment-emergent adverse events (TEAE). times to beginning of symptom relief, reduction in severity, and complete resolution. At data cutoff (Jan 31, 2024), 84 participants (mean age: 35.9 years; 14.3% 12), and complete attack resolution: 21.02h (7.22->24). No evidence of a diminished response over repeated treatments of attacks was observed. Oral sebetralstat enabled compliance with treatment guidelines. No new safety signals were observed, and effectiveness for repeated attacks was consistent with the KONFIDENT trial results.

12 March 2023 in Clinical Pediatrics
Verified
Journal Article
Open access
RTRaffi Tachdjian
Raffi Tachdjian
AKAllen P. Kaplan
Allen P. Kaplan
Hereditary angioedema (HAE) is a rare autosomal-dominant disorder; most cases are characterized by low plasma levels of C1 esterase inhibitor (C1-INH). Clinical manifestations of HAE due to C1-INH deficiency include unpredictable, acute, recurrent episodes of nonpruritic swelling that can affect the face, trunk, limbs, and the respiratory, gastrointestinal, and genitourinary tracts. Attacks can be disfiguring, disabling, painful, and even life-threatening if laryngeal swelling occurs. Symptoms of HAE generally manifest in childhood. Effective medications are available and approved to treat HAE in children. However, evidence informing use of these medications in pediatric clinical practice is limited. Hereditary angioedema management plans are critical to optimize outcomes and should address on-demand treatment for acute attacks and plans to prevent potentially fatal laryngeal attacks. The plan should also comprise a holistic approach to address nonclinical aspects of HAE, including quality of life (QoL) and psychological issues. This article provides an overview of HAE management principles that health care providers can apply to treat pediatric patients to improve their QoL.

1 February 2019 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
PBPaula J. Busse
Paula J. Busse
RTRaffi Tachdjian
Raffi Tachdjian
IMInmaculada Martinez-Saguer
Inmaculada Martinez-Saguer
PLPeng Lu
Peng Lu
CNChristina Nurse
Christina Nurse
EAEmel Aygoren-Pursun
Emel Aygoren-Pursun